HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Anti-IL-5 (mepolizumab) therapy does not alter IL-5 receptor alpha levels in patients with eosinophilic esophagitis.

AuthorsSébastien Conus, Alex Straumann, Hans-Uwe Simon
JournalThe Journal of allergy and clinical immunology (J Allergy Clin Immunol) Vol. 123 Issue 1 Pg. 269; author reply 269-70 (Jan 2009) ISSN: 1097-6825 [Electronic] United States
PMID18951621 (Publication Type: Letter, Comment)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Cytokines
  • Interleukin-5
  • Receptors, Interleukin-5
  • mepolizumab
Topics
  • Adolescent
  • Adult
  • Antibodies, Monoclonal (therapeutic use)
  • Antibodies, Monoclonal, Humanized
  • Cytokines (biosynthesis)
  • Enzyme-Linked Immunosorbent Assay
  • Eosinophilia (blood, drug therapy)
  • Eosinophils (drug effects)
  • Female
  • Flow Cytometry
  • Fluorescent Antibody Technique
  • Humans
  • Interleukin-5 (antagonists & inhibitors, blood)
  • Male
  • Middle Aged
  • Receptors, Interleukin-5 (blood, drug effects)
  • T-Lymphocyte Subsets (drug effects)
  • T-Lymphocytes (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: